Top

Drugs

Published in:

01-03-2004 | Adis Drug Profile

Ciclesonide

A Viewpoint by Noël J.J. Schlösser

Author: Noël J. J. Schlösser

Published in: Drugs | Issue 5/2004

Excerpt

Ciclesonide is a new, non-halogenated inhaled corticosteroid that is on-site activated by endogenous esterases in the airways. It is administered as an inactive compound and most of it is converted to the active metabolite only once it reaches the target organ: the lungs. Ciclesonide has essentially no oropharyngeal side effects and suppresses endogenous cortisol only to a minimal extent. The active metabolite of R-ciclesonide is referred to as desisobutyryl-ciclesonide (des-CIC). Des-CIC has a 5.2-fold higher affinity for the corticosteroid receptor than the metabolite of the S-epimer. …

Title: Ciclesonide
A Viewpoint by Noël J.J. Schlösser
Author: Noël J. J. Schlösser
Publication date: 01-03-2004
Publisher: Springer International Publishing
Published in: Drugs / Issue 5/2004
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200464050-00007

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Ciclesonide

A Viewpoint by Noël J.J. Schlösser

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2004

Treatment of Hepatitis C in Solid Organ Transplantation

Advanced Glycation Endproduct Crosslinking in the Cardiovascular System

Ciclesonide

Ciclesonide

Differentiating Factors Between Erythropoiesis-Stimulating Agents

Cetirizine